Search

Your search keyword '"Harata-Lee, Yuka"' showing total 21 results
Start Over Author "Harata-Lee, Yuka" Publication Year Range Last 10 years
21 results on '"Harata-Lee, Yuka"'

6. Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]

Author

Wainwright, Cherry L., primary, Teixeira, Mauro M., additional, Adelson, David L., additional, Buenz, Eric J., additional, David, Bruno, additional, Glaser, Keith B., additional, Harata-Lee, Yuka, additional, Howes, Melanie-Jayne R., additional, Izzo, Angelo A., additional, Maffia, Pasquale, additional, Mayer, Alejandro M.S., additional, Mazars, Claire, additional, Newman, David J., additional, Lughadha, Eimear Nic, additional, Pimenta, Adriano M.C., additional, Parra, John A.A., additional, Qu, Zhipeng, additional, Shen, Hanyuan, additional, Spedding, Michael, additional, and Wolfender, Jean-Luc, additional

Published
2022
Full Text
View/download PDF

7. Future directions for the discovery of natural product-derived immunomodulating drugs

Author

Wainwright, Cherry L., Teixeira, Mauro M., Adelson, David L., Buenz, Eric J., David, Bruno, Glaser, Keith B., Harata-Lee, Yuka, Howes, Melanie-Jayne R., Izzo, Angelo A., Maffia, Pasquale, Mayer, Alejandro M.S., Mazars, Claire, Newman, David J., Nic Lughadha, Eimear, Pimenta, Adriano M.C., Parra, John A.A., Qu, Zhipeng, Shen, Hanyan, Spedding, Michael, and Wolfender, Jean-Luc

Abstract

Drug discovery from natural sources is going through a renaissance, having spent many decades in the shadow of synthetic molecule drug discovery, despite the fact that natural product-derived compounds occupy a much greater chemical space than those created through synthetic chemistry methods. With this new era comes new possibilities, not least the novel targets that have emerged in recent times and the development of state-of-the-art technologies that can be applied to drug discovery from natural sources. Although progress has been made with some immunomodulating drugs, there remains a pressing need for new agents that can be used to treat the wide variety of conditions that arise from disruption, or over-activation, of the immune system; natural products may therefore be key in filling this gap. Recognising that, at present, there is no authoritative article that details the current state-of-the-art of the immunomodulatory activity of natural products, this in-depth review has arisen from a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) Natural Products and Immunopharmacology, with contributions from a Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation number of world-leading researchers in the field of natural product drug discovery, to provide a “position statement” on what natural products has to offer in the search for new immunomodulatory argents. To this end, we provide a historical look at previous discoveries of naturally occurring immunomodulators, present a picture of the current status of the field and provide insight into the future opportunities and challenges for the discovery of new drugs to treat immune-related diseases.

Published
2022

9. ACKR4 restrains antitumor immunity by regulating CCL21

Author

Whyte, Carly E., primary, Osman, Maleika, additional, Kara, Ervin E., additional, Abbott, Caitlin, additional, Foeng, Jade, additional, McKenzie, Duncan R., additional, Fenix, Kevin A., additional, Harata-Lee, Yuka, additional, Foyle, Kerrie L., additional, Boyle, Sarah T., additional, Kochetkova, Marina, additional, Aguilera, Amelia Roman, additional, Hou, Jiajie, additional, Li, Xian-Yang, additional, Armstrong, Mark A., additional, Pederson, Stephen M., additional, Comerford, Iain, additional, Smyth, Mark J., additional, and McColl, Shaun R., additional

Published
2020
Full Text
View/download PDF

21. ACKR4 restrains antitumor immunity by regulating CCL21

Author

Marina Kochetkova, Mark A. Armstrong, Caitlin Abbott, Kerrie L Foyle, Ervin E. Kara, Kevin A. Fenix, Jade Foeng, Jiajie Hou, Yuka Harata-Lee, Maleika Osman, Stephen Pederson, Sarah T. Boyle, Carly E. Whyte, Shaun R. McColl, Duncan R. McKenzie, Xian-Yang Li, Amelia Roman Aguilera, Mark J. Smyth, Iain Comerford, Whyte, Carly E, Osman, Maleika, Kara, Ervin E, Abbott, Caitlin, Foeng, Jade, McKenzie, Duncan R, Fenix, Kevin A, Harata-Lee, Yuka, Foyle, Kerrie L, Boyle, Sarah T, Kochetkova, Marina, Aguilera, Amelia Roman, Hou, Jian, Li, Xian-Yang, Armstrong, Mark A, Pederson, Stephen M, Comerford, Iain, Smyth, Mark J, and McColl, Shaun R

Subjects
endocrine system, medicine.medical_treatment, T cell, Immunology, CD8-Positive T-Lymphocytes, Receptors, CCR, T-cell, Antigens, CD, Neoplasms, medicine, Immunology and Allergy, Animals, Humans, tumor microenvironment (TME), Neoplasm Metastasis, Solid Tumors, Immune Checkpoint Inhibitors, Cell Proliferation, Tumor microenvironment, Chemokine CCL21, Chemistry, Cell growth, Immunity, Brief Definitive Report, Immunotherapy, Dendritic cell, Dendritic Cells, Survival Analysis, Immune checkpoint, Mice, Inbred C57BL, Disease Models, Animal, medicine.anatomical_structure, tumor specific T cells, Cancer research, Stromal Cells, Integrin alpha Chains, CD8, CCL21
Abstract

Whyte et al. demonstrate that regulation of intratumor CCL21 and DC trafficking from tumors by the atypical chemokine receptor 4 curtails intratumor CD8+ T cell accumulation and immunotherapy efficacy., Current immunotherapies involving CD8+ T cell responses show remarkable promise, but their efficacy in many solid tumors is limited, in part due to the low frequency of tumor-specific T cells in the tumor microenvironment (TME). Here, we identified a role for host atypical chemokine receptor 4 (ACKR4) in controlling intratumor T cell accumulation and activation. In the absence of ACKR4, an increase in intratumor CD8+ T cells inhibited tumor growth, and nonhematopoietic ACKR4 expression was critical. We show that ACKR4 inhibited CD103+ dendritic cell retention in tumors through regulation of the intratumor abundance of CCL21. In addition, preclinical studies indicate that ACKR4 and CCL21 are potential therapeutic targets to enhance responsiveness to immune checkpoint blockade or T cell costimulation.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results